Sino Biopharmaceutical (01177) said its revenue increased 11.6% year-on year to HK$4,168 million for the three months ended 31 March 2016.
Profit attributable to the group before and after accounted for unrealized fair value gains and losses of equity investments and financial assets increased by 35.2% and increased by 32% to HK$543 million and HK$528 million respectively.
Basic earnings per share before and after accounted for unrealized fair value gains and losses of equity investments and financial assets rose to 7.33 HK cents and 7.12 HK cents, respectively, a growth of 35.2% and 31.9%, when compared to the last corresponding period.
The company has declared a first quarter dividend of 1.5 HK cents per share (2015 1Q: 1.5 HK cents).
全新節目《說說心理話》青少年不可以戀愛！？真實個案講述驚心動魄經歷► 即睇
